Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 18, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Triamcinolone Acetonide Injectable Suspension USP, 40 mg/mL (Single-Dose and Multiple-Dose Vials)".